Loading asset research
Evommune Inc. Common Stock
EVMNNYSE · USD · StocksQuote as of · Exchange session not verified$10.54
-0.19%
Today
EVMN
Loading 1D prices…
Market cap
$382.5M
Volume
388.9K
52w high
$33.2052w low
$10.30Company profile
Evommune Inc. Common Stock
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
NYSE
Display currency
USD
Location
Palo Alto, CA, United States
Employees
48
Fiscal year end
1231
CIK
2044725
Session & valuation
Open$10.66
Previous close$10.56
Day high$10.82
Day low$10.50
30-day avg. volume598K
Outstanding shares36.3M
Diluted EPS-$11.22
Latest annual period
P/E (trailing)-0.94
P/E (forward)-3.11
Price / book1.38
Beta—
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| TTRXTurn Therapeutics Inc. Common Stock | $385.4M | $0.00 | — | -$0.12 | -5.16% | Buy |
| ENTAEnanta Pharmaceuticals Inc. Common Stock | $377.5M | $50.1M | -88.82% | -$1.54 | +1.97% | Buy |
| BIOABioAge Labs Inc. Common Stock | $389.7M | $9M | -896.11% | -$2.24 | -1.85% | Buy |
| PREPrenetics Global Limited Class A Ordinary Share | $393.8M | $92.4M | -40.82% | -$4.15 | -0.80% | Buy |
| GALTGalectin Therapeutics Inc. Common Stock | $394.3M | $0.00 | — | -$0.48 | +0.38% | Buy |